Ten New License-Out Deals by Chinese Firms in Seven Weeks
Assets in Phase 3 Clinical Trials and Approved Products Also Go Global

The overseas technology export (license-out) momentum of Chinese pharmaceutical and biotech companies continues into the second half of the year. Over the past seven weeks, the largest newly signed license-out deal has approached 15 trillion won. As transaction areas expand beyond anticancer drugs to respiratory, autoimmune, and obesity drugs, there is also a growing trend of transferring assets that have reached the late stages of clinical development overseas.


According to data from global biotech investment advisory firm YAFO as of August 26, over the period from July 1 to August 21, Chinese pharmaceutical and biotech companies signed 10 new overseas license-out deals. The combined maximum contract value disclosed for nine of these deals amounts to approximately USD 10.5 billion (about KRW 14.5 trillion). The maximum contract value includes upfront payments as well as milestones related to development, approval, and commercialization phases.


Nearly 15 Trillion Won in the Second Half Already... China's 'Bio Ambition' Accelerates View original image

In July, six new deals were signed. Hansoh Pharma transferred the global rights, excluding the Greater China region, for its oral interleukin (IL)-23 receptor antagonist 'HS-20118' to U.S.-based Aveo Therapeutics for up to USD 2.3 billion (about KRW 3.18 trillion).


Chengdu Tianqi Pharma transferred the rights, excluding mainland China, for its phase 3 asthma and chronic obstructive pulmonary disease (COPD) candidate 'TQC3721' to AstraZeneca for up to USD 1.9 billion (about KRW 2.63 trillion). Dizal Pharma and Innovent Biologics each finalized technology export agreements worth over USD 1 billion for treatments in lung cancer and autoimmune diseases, respectively.


In August, large-scale deals involving late-stage clinical assets stood out. Alphamab Oncology transferred the global rights, excluding the Greater China region, for its dual-specific antibody-drug conjugate (ADC) 'JSKN016', which simultaneously targets TROP2 and HER3, to U.S.-based Pathos AI for up to USD 2.093 billion (about KRW 2.89 trillion). JSKN016 is currently undergoing late-stage clinical trials targeting triple-negative breast cancer and related indications. Gan & Lee Pharmaceuticals also transferred the European rights for its phase 3 obesity and type 2 diabetes treatment 'Bopanglutide' to Italy’s Menarini for up to USD 821 million (about KRW 1.14 trillion).


The expansion of license-out activity in China became prominent in the first half of the year. According to data from China’s National Medical Products Administration (NMPA), in the first half of this year, there were 81 overseas license-outs of innovative new drugs by Chinese companies, with the maximum overall deal size reaching approximately USD 110 billion (about KRW 152 trillion), setting a new record.


The phase at which deals are made is noteworthy. In addition to deals involving early-stage candidates, there is a rising number of cases where assets are transferred after securing clinical data or developing them up to the regulatory approval stage. For global pharmaceutical companies, bringing in assets that already have efficacy and safety data in humans reduces the risk of early development failure and shortens the development timeline. For Chinese companies, advancing the development phase allows for larger upfront payments and total contract values.


This fierce competition among global pharmaceutical companies to acquire innovative drugs is also prompting large-scale license-out deals from Korean companies. On August 24, Hanmi Pharm transferred global development, manufacturing, and commercialization rights, excluding Korea, for its new obesity and metabolic disease drug candidate 'HM17321' to Genentech, a subsidiary of Roche Group. The maximum contract amount, including an upfront payment of USD 190 million (about KRW 262.9 billion), totals USD 2.3 billion (about KRW 3.2 trillion).



Alteogen transferred its subcutaneous injection (SC) formulation platform 'ALT-B4' for up to USD 365 million (about KRW 505 billion), and NeoImmuneTech transferred rights related to thymic insufficiency for 'NT-I7' for up to USD 260 million (about KRW 359.7 billion). According to data compiled by the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, the total value of publicly disclosed license-out contracts by Korean pharmaceutical and biotech companies this year amounts to KRW 17.2472 trillion.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing